weight-lossclinical-trials
Orforglipron
Orforglipron (LY3502970)
Overview
The most anticipated upcoming weight loss drug - the first oral non-peptide GLP-1 receptor agonist. Unlike current oral options, it does not require fasting before consumption, potentially removing a major barrier to adherence.
Mechanism of Action
Small molecule that activates GLP-1 receptors orally without the peptide structure. Provides similar effects to injectable GLP-1s but in pill form.
Popular Research Uses
- Weight loss (investigational)
- Diabetes management (investigational)
- Oral alternative to injections
Potential Side Effects
- Nausea (reported in trials)
- Diarrhea
- Vomiting
- Constipation
- Unknown - trials ongoing
Warnings
- NOT FDA approved - still in clinical trials
- Approval timeline remains uncertain; monitor official FDA updates
- No gray market versions should be trusted
- Unknown long-term effects
- Do not confuse with other oral GLP-1s
Dosage Information
Wait for FDA approval. This will be a game-changer for those who cannot tolerate injections.